妓院一钑片免看黄大片,亚洲av无码成人精品国产,亚洲AV综合色区无码专区桃色,免费A级毛片在线播放不收费

瑞士Molecular Partners  


Molecular Partners is a privately owned biopharmaceutical company, located in Zurich, Switzerland, that is pioneering the development of a novel class of targeted protein therapeutics termed DARPins. DARPins are as target specific and potent as monoclonal antibodies. Yet, being small proteins, they overcome the known limitations of conventional protein-based therapeutic approaches.

We address real medical needs and develop cutting-edge medicine based on innovative DARPin products.

The DARPin platform has rapidly generated a differentiated pipeline of drug candidates. The most advanced DARPin is MP0112, an inhibitor of VEGF, which has completed two separate Phase I/IIa clinical trials in wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), the most common causes for vision loss. Further products are in research and preclinical development. We balance our internal drug development efforts with strategic alliances with renowned pharmaceutical companies.

Molecular Partners is backed by a very strong international syndicate of institutional and corporate investors.